Serum microRNA expression levels in Turkish patients with Parkinson's disease
Betul Ozdilek1,2, Berna Demircan3
1Department of Neurology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
Objectives:
To determine the serum expression levels of seven candidate microRNAs (miRNA); miR-19a, miR-19b, miR-29a, miR-29c, miR-181, miR-195 and miR-221 in Turkish patients with Parkinson's disease (PD) and explored their potential role in the diagnosis of PD. We further described the relationship between these miRNAs with the clinical findings and treatment of PD.
Materials And Methods:
The study included 51 PD patients and 20 healthy controls. The clinical severity of disease was assessed using the Hoehn Yahr staging scale and the Unified Parkinson's Disease Rating Scale (UPDRS). Venous blood samples were taken after fasting for 12 h, then centrifuged. Obtained serum samples were stored until analysis of miRNA. In the laboratory, expression levels of these miRNAs were analyzed using a real-time PCR instrument. Receiver-operating characteristic analysis and area-under the-curve (AUC) was used to evaluate these miRNA levels as potential diagnostic biomarkers for PD.
Results:
miR-29c expression levels were increased significantly for PD patients compared to healthy controls. There were no significant differences in levels of other miRNAs between PD patients and controls. The AUC of miR-29c was 0.689. The sensitivity and specificity of this diagnostic test was 54.9% and 80.0%, respectively. miR-195 level was found to have a significant positive correlation only with age. Significant negative correlation was found between miR-29a level and UPDRS total score. miR-19b was found higher in ropinirole drug used group than that of pramipexole group.
Conclusion:
This study suggests that serum miR-29c expression level might be potential biomarker in the diagnosis of Turkish Parkinson patients.
Insights
Serum miR-29c levels may help diagnose Parkinson's disease (PD) in Turkish patients. This microRNA showed increased expression in PD patients, suggesting its potential as a diagnostic biomarker.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder.
- Early diagnosis of PD is crucial for effective management.
- MicroRNAs (miRNAs) are implicated in various diseases, including neurodegenerative conditions.
Purpose of the Study:
- To investigate serum microRNA expression levels in Turkish Parkinson's disease patients.
- To evaluate the potential of specific microRNAs as diagnostic biomarkers for PD.
- To explore the relationship between miRNA levels and clinical aspects of PD.
Main Methods:
- Serum samples from 51 PD patients and 20 healthy controls were analyzed.
- Expression levels of seven candidate miRNAs (miR-19a, miR-19b, miR-29a, miR-29c, miR-181, miR-195, miR-221) were quantified using real-time PCR.
- Clinical severity was assessed using Hoehn Yahr and UPDRS scales. Receiver-operating characteristic (ROC) analysis was employed.
Main Results:
- Serum miR-29c levels were significantly elevated in PD patients compared to controls.
- miR-29c demonstrated an Area Under the Curve (AUC) of 0.689, with 54.9% sensitivity and 80.0% specificity.
- miR-195 correlated positively with age, and miR-29a negatively with UPDRS total score. miR-19b levels differed between users of ropinirole and pramipexole.
Conclusions:
- Serum miR-29c may serve as a potential diagnostic biomarker for Parkinson's disease in the Turkish population.
- Further research is warranted to validate miR-29c as a reliable biomarker for PD diagnosis.
- Specific miRNAs may correlate with disease progression and treatment in PD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:15Parkinson's Disease: Overview
01:22MicroRNAs